JP2022516283A5 - - Google Patents

Info

Publication number
JP2022516283A5
JP2022516283A5 JP2021538754A JP2021538754A JP2022516283A5 JP 2022516283 A5 JP2022516283 A5 JP 2022516283A5 JP 2021538754 A JP2021538754 A JP 2021538754A JP 2021538754 A JP2021538754 A JP 2021538754A JP 2022516283 A5 JP2022516283 A5 JP 2022516283A5
Authority
JP
Japan
Prior art keywords
sequence
raav
item
itr
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021538754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516283A (ja
JP7531495B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012131 external-priority patent/WO2020142653A1/en
Publication of JP2022516283A publication Critical patent/JP2022516283A/ja
Publication of JP2022516283A5 publication Critical patent/JP2022516283A5/ja
Priority to JP2024031460A priority Critical patent/JP7746437B2/ja
Application granted granted Critical
Publication of JP7531495B2 publication Critical patent/JP7531495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021538754A 2019-01-04 2020-01-03 ウイルソン病を処置するための遺伝子治療構築物 Active JP7531495B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024031460A JP7746437B2 (ja) 2019-01-04 2024-03-01 ウイルソン病を処置するための遺伝子治療構築物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788324P 2019-01-04 2019-01-04
US62/788,324 2019-01-04
US201962834830P 2019-04-16 2019-04-16
US62/834,830 2019-04-16
PCT/US2020/012131 WO2020142653A1 (en) 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031460A Division JP7746437B2 (ja) 2019-01-04 2024-03-01 ウイルソン病を処置するための遺伝子治療構築物

Publications (3)

Publication Number Publication Date
JP2022516283A JP2022516283A (ja) 2022-02-25
JP2022516283A5 true JP2022516283A5 (cg-RX-API-DMAC7.html) 2023-01-19
JP7531495B2 JP7531495B2 (ja) 2024-08-09

Family

ID=69528954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538754A Active JP7531495B2 (ja) 2019-01-04 2020-01-03 ウイルソン病を処置するための遺伝子治療構築物
JP2024031460A Active JP7746437B2 (ja) 2019-01-04 2024-03-01 ウイルソン病を処置するための遺伝子治療構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024031460A Active JP7746437B2 (ja) 2019-01-04 2024-03-01 ウイルソン病を処置するための遺伝子治療構築物

Country Status (21)

Country Link
US (2) US12338450B2 (cg-RX-API-DMAC7.html)
EP (2) EP3906066B1 (cg-RX-API-DMAC7.html)
JP (2) JP7531495B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210112339A (cg-RX-API-DMAC7.html)
CN (1) CN113518628B (cg-RX-API-DMAC7.html)
AU (1) AU2020204679B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021013140A2 (cg-RX-API-DMAC7.html)
CO (1) CO2021010088A2 (cg-RX-API-DMAC7.html)
DK (1) DK3906066T5 (cg-RX-API-DMAC7.html)
ES (2) ES2970216T3 (cg-RX-API-DMAC7.html)
FI (1) FI3906066T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231750T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065782T2 (cg-RX-API-DMAC7.html)
IL (1) IL284554A (cg-RX-API-DMAC7.html)
MX (1) MX2021008135A (cg-RX-API-DMAC7.html)
PL (1) PL3906066T3 (cg-RX-API-DMAC7.html)
PT (1) PT3906066T (cg-RX-API-DMAC7.html)
SG (1) SG11202106855YA (cg-RX-API-DMAC7.html)
TW (1) TWI848038B (cg-RX-API-DMAC7.html)
WO (1) WO2020142653A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104515B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863181B1 (ko) 2016-12-30 2025-09-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 윌슨병을 치료하기 위한 유전자 치료
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
MX2021013913A (es) * 2019-05-14 2022-03-17 Univ Duke Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
CN113694218A (zh) * 2021-08-30 2021-11-26 昆明理工大学 一种atp7b基因p992l突变的基因修复治疗载体
AU2022407655A1 (en) * 2021-12-10 2024-06-20 Aavantibio, Inc. Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
KR20240114769A (ko) * 2021-12-10 2024-07-24 애반티바이오, 인크. 증진된 발현을 위해 선택된 코작 서열을 포함하는 조성물
EP4677077A4 (en) * 2023-03-06 2026-07-29 Lingyi Biotech Co Ltd TRUNCATED ATP7B GENE AND ITS USAGE
JP2026508707A (ja) * 2023-03-22 2026-03-11 スカイライン、セラピューティクス、リミテッド ウィルソン病の遺伝子療法のための組換えaav
WO2025002226A1 (zh) * 2023-06-28 2025-01-02 迈威(上海)生物科技股份有限公司 编码atp7b的核酸、腺相关病毒载体及其在制备防治肝豆状核变性的药物中的应用
CN120882865A (zh) * 2023-07-28 2025-10-31 凌意(杭州)生物科技有限公司 用于治疗威尔逊病的多核苷酸

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
WO2003038049A2 (en) * 2001-10-29 2003-05-08 Renovis, Inc. Method for isolating cell-type specific mrnas
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DE10156121A1 (de) 2001-11-16 2003-05-28 Wolfgang Stremmel Somatische Gentherapie mit Vektoren, die einen verkürzten metallsensitiven Promotor besitzen, zur Behandlung des Morbus Wilson sowie anderer Erkrankungen, die mit Veränderungen im Metallstoffwechsel einhergehen, wie z.B. Alzheimer-Erkrankung
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
CN107208105A (zh) 2014-12-17 2017-09-26 基础应用医学研究基金会 用于治疗威尔森病的核酸构建体和基因治疗载体
US11118238B2 (en) 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
KR102863181B1 (ko) 2016-12-30 2025-09-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 윌슨병을 치료하기 위한 유전자 치료
CA3118936A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
WO2023230466A1 (en) * 2022-05-23 2023-11-30 Lutsenka Svetlana Compositions and methods for treating wilson's disease

Similar Documents

Publication Publication Date Title
JP2023514204A5 (cg-RX-API-DMAC7.html)
HRP20231750T1 (hr) Konstrukti genske terapije za liječenje wilsonove bolesti
US10308957B2 (en) rAAV vectors and methods for transduction of photoreceptors and RPE cells
JP2023520402A5 (cg-RX-API-DMAC7.html)
AU2018304194B2 (en) Apheresis methods and uses
JP2020514286A5 (cg-RX-API-DMAC7.html)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2020510428A5 (cg-RX-API-DMAC7.html)
JP2020519292A5 (cg-RX-API-DMAC7.html)
WO2016210170A9 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CN104520428A (zh) 将基因转移到细胞、器官和组织的aav载体组合物和方法
TW202144575A (zh) 使用aav及治療調配物之苯酮尿症治療
JP2023503850A5 (cg-RX-API-DMAC7.html)
JP2023536883A5 (cg-RX-API-DMAC7.html)
JP2022533448A5 (cg-RX-API-DMAC7.html)
WO2024255448A1 (zh) 凝血因子fviii蛋白变体、表达载体和用途
JP2024527742A5 (cg-RX-API-DMAC7.html)
JP2024056832A5 (cg-RX-API-DMAC7.html)
JP2023076698A (ja) 21-ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法
EP4444364A1 (en) Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector
JP2025090820A5 (cg-RX-API-DMAC7.html)
JP2024515626A5 (cg-RX-API-DMAC7.html)
JP2023534293A5 (cg-RX-API-DMAC7.html)
JP2021533799A (ja) 第ix因子をコードするヌクレオチド
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy